argenx NV ADR (ARGX)vsAlterity Therapeutics Ltd (ATHE)
ARGX
argenx NV ADR
$835.99
-0.30%
HEALTHCARE · Cap: $50.40B
ATHE
Alterity Therapeutics Ltd
$4.02
-2.52%
HEALTHCARE · Cap: $88.31M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 71361% more annual revenue ($4.74B vs $6.64M). ARGX leads profitability with a 31.4% profit margin vs -219.9%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
ATHE
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+62.4%
Fair Value
$2217.64
Current Price
$835.99
$1381.65 discount
Intrinsic value data unavailable for ATHE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 30.0%
Revenue surging 62.6% year-over-year
Earnings expanding 114.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Revenue surging 74.6% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 176.7x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -46.4% — below average capital efficiency
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 30.0%. Revenue growth of 62.6% demonstrates continued momentum.
Bull Case : ATHE
The strongest argument for ATHE centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 74.6% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : ATHE
The primary concerns for ATHE are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ARGX profiles as a growth stock while ATHE is a hypergrowth play — different risk/reward profiles.
ATHE is growing revenue faster at 74.6% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 26/100), backed by strong 31.4% margins and 62.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Alterity Therapeutics Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinson's disease and other neurodegenerative diseases in Australia. The company is headquartered in Melbourne, Australia.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?